5kvf: Difference between revisions
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5kvf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5kvf OCA], [http://pdbe.org/5kvf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5kvf RCSB], [http://www.ebi.ac.uk/pdbsum/5kvf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5kvf ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5kvf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5kvf OCA], [http://pdbe.org/5kvf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5kvf RCSB], [http://www.ebi.ac.uk/pdbsum/5kvf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5kvf ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Zika virus (ZIKV) infection during pregnancy has emerged as a global public health problem because of its ability to cause severe congenital disease. Here, we developed six mouse monoclonal antibodies (mAbs) against ZIKV including four (ZV-48, ZV-54, ZV-64, and ZV-67) that were ZIKV specific and neutralized infection of African, Asian, and American strains to varying degrees. X-ray crystallographic and competition binding analyses of Fab fragments and scFvs defined three spatially distinct epitopes in DIII of the envelope protein corresponding to the lateral ridge (ZV-54 and ZV-67), C-C' loop (ZV-48 and ZV-64), and ABDE sheet (ZV-2) regions. In vivo passive transfer studies revealed protective activity of DIII-lateral ridge specific neutralizing mAbs in a mouse model of ZIKV infection. Our results suggest that DIII is targeted by multiple type-specific antibodies with distinct neutralizing activity, which provides a path for developing prophylactic antibodies for use in pregnancy or designing epitope-specific vaccines against ZIKV. | |||
Structural Basis of Zika Virus-Specific Antibody Protection.,Zhao H, Fernandez E, Dowd KA, Speer SD, Platt DJ, Gorman MJ, Govero J, Nelson CA, Pierson TC, Diamond MS, Fremont DH Cell. 2016 Jul 26. pii: S0092-8674(16)30927-8. doi: 10.1016/j.cell.2016.07.020. PMID:27475895<ref>PMID:27475895</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 5kvf" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||